secwatch.observer — SEC 8-K summary
======================================

Issuer:     LISATA THERAPEUTICS, INC. (LSTA)
CIK:        0000320017
Form:       8-K
Filed at:   2024-05-09T23:59:59+00:00
Accession:  0000320017-24-000029
Event type: earnings
Sentiment:  neutral
Materiality: 0.70
Item codes: 2.02, 7.01, 9.01
LLM model:  deepseek-v4-flash:cloud@v2

Lisata Q1 net loss $5.4M; ASCEND Phase 2b data on track for Q4 2024
-------------------------------------------------------------------

- Cash, equivalents and marketable securities $43.3M as of Mar 31, 2024; funding operations into early 2026.
- Net loss $5.4M vs $6.2M in Q1 2023; operating expenses $6.6M, down 3.6% YoY.
- Top-line data from pivotal Phase 2b ASCEND trial (mPDAC) expected Q4 2024; full data set mid-2025.
- Received FDA Orphan Drug and Rare Pediatric Disease designations for certepetide in osteosarcoma.
- BOLSTER (cholangiocarcinoma) enrollment completion expected Q3 2024; CENDIFOX on track for year-end 2024.

Source:
  EDGAR index:    https://www.sec.gov/Archives/edgar/data/320017/000032001724000029/0000320017-24-000029-index.htm
  Primary doc:    https://www.sec.gov/Archives/edgar/data/320017/000032001724000029/clbs-20240509.htm
  HTML page:      https://secwatch.observer/filing/0000320017-24-000029

License: Source filings: public domain (SEC EDGAR). Summaries (headline + bullets): CC-BY-4.0; attribute https://secwatch.observer